Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$124 Mln
P/E Ratio
--
P/B Ratio
1.41
Industry P/E
--
Debt to Equity
0.46
ROE
-0.5 %
ROCE
-36.33 %
Div. Yield
0 %
Book Value
1.75
EPS
-1.03
CFO
$-247.34 Mln
EBITDA
$-266.31 Mln
Net Profit
$-279.60 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Sight Sciences Inc (SGHT)
| -27.61 | -3.13 | -7.22 | -49.62 | -34.20 | -- | -- |
|
BSE Sensex
| 0.39 | 6.40 | 1.96 | 7.69 | 10.43 | 20.75 | 10.61 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Sight Sciences Inc (SGHT)
| -29.26 | -57.74 | -30.51 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.17 | 10,493.90 | 14.81 | 12.69 | |
| 71.00 | 9,951.16 | 96.47 | 2.52 | |
| 151.99 | 8,216.59 | -- | -25.23 | |
| 277.36 | 10,486.34 | 777.89 | 1.2 |
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. It operates through two segments, Surgical Glaucoma and... Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform procedures for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure; and SION surgical instrument, a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also offers TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. Address: 4040 Campbell Avenue, Menlo Park, CA, United States, 94025 Read more
Co-Founder, President, CEO & Director
Mr. Paul Badawi
Co-Founder, President, CEO & Director
Mr. Paul Badawi
Headquarters
Menlo Park, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Sight Sciences Inc (SGHT) stood at $ 143 Mln as on 31-Dec-24
The share price of Sight Sciences Inc (SGHT) is $2.64 (NASDAQ) as of 17-Apr-2025 15:40 EDT. Sight Sciences Inc (SGHT) has given a return of -34.2% in the last 3 years.
Sight Sciences Inc (SGHT) has a market capitalisation of $ 124 Mln as on 15-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Sight Sciences Inc (SGHT) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Sight Sciences Inc (SGHT) and enter the required number of quantities and click on buy to purchase the shares of Sight Sciences Inc (SGHT).
Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform procedures for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure; and SION surgical instrument, a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The company also offers TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. Address: 4040 Campbell Avenue, Menlo Park, CA, United States, 94025
The CEO & director of Mr. Paul Badawi. is Sight Sciences Inc (SGHT), and CFO & Sr. VP is Mr. Paul Badawi.
There is no promoter pledging in Sight Sciences Inc (SGHT).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,083
|
|
|
1,061
|
|
|
1,022
|
|
|
889
|
| Sight Sciences Inc (SGHT) | Ratios |
|---|---|
|
Return on equity(%)
|
-49.59
|
|
Operating margin(%)
|
-58.36
|
|
Net Margin(%)
|
-64.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Sight Sciences Inc (SGHT) was $0 Mln.
$0.03
(
